Benitec Biopharma (NASDAQ:BNTC) Given New $35.00 Price Target at HC Wainwright

Benitec Biopharma (NASDAQ:BNTC) had its price objective increased by HC Wainwright from $28.00 to $35.00 in a research report report published on Tuesday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on BNTC. JMP Securities set a $22.00 price objective on shares of Benitec Biopharma in a research report on Tuesday. Wall Street Zen upgraded shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Citigroup restated an “outperform” rating on shares of Benitec Biopharma in a research report on Tuesday. Zacks Research downgraded shares of Benitec Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. Finally, Oppenheimer restated an “outperform” rating and set a $29.00 price objective (down previously from $35.00) on shares of Benitec Biopharma in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Benitec Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $25.83.

Benitec Biopharma Price Performance

BNTC opened at $15.71 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 54.67 and a current ratio of 54.67. The stock has a market capitalization of $412.39 million, a P/E ratio of -10.69 and a beta of 0.41. The company’s 50-day simple moving average is $14.48 and its two-hundred day simple moving average is $13.78. Benitec Biopharma has a 52-week low of $9.10 and a 52-week high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.18). As a group, analysts predict that Benitec Biopharma will post -1.48 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Simplify Asset Management Inc. raised its position in Benitec Biopharma by 13.8% in the third quarter. Simplify Asset Management Inc. now owns 78,725 shares of the biotechnology company’s stock worth $1,105,000 after acquiring an additional 9,552 shares during the period. Bank of America Corp DE raised its position in Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,587 shares during the period. Ameriprise Financial Inc. raised its position in Benitec Biopharma by 219.4% in the second quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company’s stock worth $1,286,000 after acquiring an additional 75,507 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Benitec Biopharma in the second quarter worth approximately $93,000. Finally, Marshall Wace LLP bought a new position in Benitec Biopharma in the second quarter worth approximately $503,000. 52.19% of the stock is currently owned by institutional investors.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.